Jeffrey Leiden, M.D., Ph.D.
Chair, President and CEO
Dr. Leiden joined Vertex's executive team in December 2011, and has served as a member of Vertex's board of directors since 2009. Dr. Leiden brings to Vertex more than 20 years of scientific, commercial and financial experience in the pharmaceutical and biotechnology industries and clinical experience in academia as a practicing cardiologist and molecular biologist.
Dr. Leiden began his career in academia as a practicing cardiologist and molecular biologist. From 1987 to 2000, Dr. Leiden held several academic appointments, including roles as Chief of Cardiology at the University of Chicago and Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital. During his academic career, Dr. Leiden was also involved in starting several biotechnology companies including Vical and Cardiogene.
Dr. Leiden held a number of board positions for pharmaceutical and biotechnology companies, including the role of non-executive Vice Chairman for Shire Pharmaceuticals plc. He was also a member of the Board of Directors of Millennium Pharmaceuticals, Inc. He is an elected member of both the American Academy of Arts and Sciences, and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.
Stuart A. Arbuckle
Executive Vice President and Chief Commercial Officer
Mr. Arbuckle joined Vertex in September 2012. As Vertex’s Executive Vice President and Chief Commercial Officer, Mr. Arbuckle oversees Vertex’s global commercial team, which is responsible for the company’s sales, marketing, patient support, market research and other activities that support the approved use of Vertex’s two medicines. Read more
Mr. Arbuckle has more than 25 years of experience in leading global sales and marketing efforts at biopharmaceutical companies. Prior to joining Vertex, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc., a 17,000-person biotechnology company. As Vice President and General Manager, Oncology Business Unit, he led sales, marketing, patient advocacy and access efforts for Amgen’s portfolio of cancer medicines. He was responsible for sales and marketing efforts for Aranesp®, Neulasta® and NEUPOGEN®, which accounted for more than $5 billion in sales in 2011, and led the successful launches of XGEVA® and Nplate®. Most recently, he served as Vice President and Regional General Manager where he led efforts to expand Amgen's presence in Japan and emerging markets in Asia, the Middle East and Africa.
Prior to these roles, Mr. Arbuckle spent more than 15 years at GlaxoSmithKline (GSK) plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He joined GSK after earning a degree in pharmacology and physiology from the University of Leeds in the United Kingdom. Mr. Arbuckle currently serves as a national board member of the Cancer Support Community, an international non-profit dedicated to providing support, education and hope to people affected by cancer, and on the Health Section Governing Board for the Biotechnology Industry Organization.
Thomas F. Connolly
Senior Vice President, Human Resources
Mr. Connolly joined Vertex in September 2012 and is the company’s Senior Vice President, Human Resources (HR). He oversees all aspects of Vertex’s HR activities, including talent acquisition and development, compensation and benefits and HR information systems. Read more
Prior to joining the company, Mr. Connolly held a number of HR leadership roles for major corporations including Managing Director/Chief HR Officer at UBS, and most recently, SVP/Chief HR Officer at MF Global. He also held HR leadership positions at Goldman Sachs, Citibank, Aetna and Lehman Brothers. Mr. Connolly brings 25 years of global HR experience to Vertex, having managed HR operations in more than 40 countries, with expatriate assignments in London, Zurich and Tokyo.
Mr. Connolly holds a Bachelor’s degree in Psychology from the University of Connecticut, a Master’s degree in Industrial/Organizational Psychology from Stevens Institute of Technology and a Master’s degree in Health Care Administration from the University of Phoenix. He also holds an MBA from Leonard N. Stern School of Business at New York University. He currently serves as a special advisor on HR and other organizational matters to Save the Children, and serves on the Advisory Board of the Center for Innovation & Change Leadership at Suffolk University.
Kenneth L. Horton
Executive Vice President and Chief Legal Officer
Mr. Horton joined Vertex in June 2012. As Vertex’s Executive Vice President and Chief Legal Officer, Mr. Horton holds responsibility for Vertex’s global legal and compliance functions. Read more
Prior to joining Vertex, Mr. Horton served as General Counsel and Executive Vice President of Corporate Development at Nordion Inc. (formerly MDS Inc.), a global health science company, from 2005 to 2011. He joined MDS from PerkinElmer, Inc., where he was Vice President, Acquisitions, Ventures and General Counsel for the Life and Analytical Sciences business unit. Mr. Horton began his legal career practicing corporate law at Ropes & Gray in Boston after working as a strategy consultant in the United States and Europe. Mr. Horton currently serves on the Board of Advisors for Beth Israel Deaconess—Needham Hospital and is formerly Chairman of Lumira Capital. Mr. Horton holds an A.B. from Dartmouth College, a J.D. from Harvard Law School and was awarded the D.A.A.D. Direktstipendium for study at the Universitaet Bonn.
Peter Mueller, Ph.D.
Executive Vice President, Global Research and Development, and Chief Scientific Officer
Dr. Mueller joined Vertex in 2003 and is the company’s Executive Vice President, Global Research and Development, and Chief Scientific Officer. He is responsible for Vertex's research and development activities, including clinical and non-clinical development, clinical operations and medical and regulatory affairs for all of Vertex's medicines in development. Read more
Prior to joining Vertex, Dr. Mueller was the Senior Vice President, Research and Development, of Boehringer Ingelheim Pharmaceuticals, Inc., with responsibility for the development of all drug candidates in the company’s worldwide portfolio in North America. During his time with Boehringer Ingelheim, Dr. Mueller oversaw the discovery, development and approval of numerous development candidates and held several positions in basic research, medicinal chemistry and management. Dr. Mueller received both an undergraduate degree and a Ph.D. in chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretic Organic Chemistry. He completed fellowships in quantum pharmacology at Oxford University and in biophysics at Rochester University.
Senior Vice President, Corporate Communications
Megan Pace is our Senior Vice President of Corporate Communications, overseeing global product and corporate public relations, internal communications, patient advocacy and corporate social responsibility. She joined Vertex in May 2010. Read more
Prior to Vertex, Ms. Pace spent six years at Genentech leading the team responsible for public affairs, product public relations and patient advocacy. She managed communications issues and initiatives supporting the approval and launch of Genentech’s new medicines, clinical and regulatory milestones, patient assistance programs and legislative priorities. She also held government affairs and public relations roles at Eli Lilly & Company, including leading global communications for their neuroscience therapies and pipeline. While at Porter Novelli, a global public relations firm, she managed disease awareness and public health campaigns for several biopharmaceutical companies and government agencies.
Ms. Pace began her career working on political campaigns in her home state of Florida and in Washington, DC. She received a B.A. from the College of Charleston.
Amit K. Sachdev
Senior Vice President, Global Government Strategy, Market Access and Value
Mr. Sachdev joined Vertex in 2007. As Vertex’s Senior Vice President, Global Government Strategy, Market Access and Value, Mr. Sachdev manages our global market access, health economics and outcomes research efforts for our approved and pipeline medicines. Read more
He also oversees our government affairs and public policy activities. In 2010, he established our first ex-US commercial operations.
Prior to Vertex, Mr. Sachdev served as Executive Vice President, Health, at the Biotechnology Industry Organization (BIO) and was Deputy Commissioner for Policy at the U.S. Food and Drug Administration (FDA) where he also held several other senior appointments beginning in 2002. From 1998 to 2002, Mr. Sachdev served as Majority Counsel to the Committee on Energy and Commerce in the U.S. House of Representatives. From 1993 to 1998, he practiced law, first at the American Chemistry Council, and then with the law firm of Ropes & Gray.
Mr. Sachdev received a B.S from Carnegie Mellon University, and a J.D. from Emory University School of Law.
Ian F. Smith
Executive Vice President and Chief Financial Officer
Ian Smith joined Vertex in November 2001. As Vertex’s Executive Vice President and Chief Financial Officer. Mr. Smith holds responsibility for core functions at Vertex, including Finance and Accounting, Investor Relations, Business Development, Information Systems and Worldwide Operations. Read more
Prior to joining Vertex, Mr. Smith served as a partner in the Life Science and Technology Practice Group of Ernst & Young LLP, an accounting firm, from 1999 to 2001.
Mr. Smith received a B.A. with honors in Accounting and Finance from Manchester Metropolitan University, and Mr. Smith is a current member of the American Institute of Certified Public Accountants, the Institute of Chartered Accountants of England and Wales, and the Financial Executives Institute.
Mr. Smith is a member of the Board of Directors of Acorda Therapeutics and is also a member of the Board of Directors of Infinity Pharmaceuticals and Chairman of their Audit Committee.